J&J-Pharmacyclics drug shows potential in high-risk leukemia patients

February 17, 2015 3:29 PM

8 0

(Reuters) - Pharmacyclics Inc said its cancer drug developed with a Johnson & Johnson unit improved overall response rate in high-risk leukemia patients.

Those administered with Imbruvica showed an overall response rate of 88 percent, while 76.6 percent survived without the disease getting worse at 24 months.

Also read: Donald Trump's Approval Rating Is In The Toilet

Read more

To category page

Loading...